Recruitment of HIV/AIDS treatment-naïve patients to clinical trials in the highly active antiretroviral therapy era: influence of gender, sexual orientation and race.
BACKGROUND
In the USA, women, racial/ethnic minorities and persons who acquire HIV infection through heterosexual intercourse represent an increasing proportion of HIV-infected persons, and yet are frequently underrepresented in clinical trials. We assessed the demographic predictors of trial participation in antiretroviral-naïve patients.


METHODS
Patients were characterized as trial participants if highly active antiretroviral therapy (HAART) was initiated within a clinical trial. Prevalence ratios (PRs) were obtained using binomial regression.


RESULTS
Between 1996 and 2006, 30% of 738 treatment-naïve patients initiated HAART in a clinical trial. Trial participation rates for men who have sex with men (MSM), heterosexual men, and women were respectively 36.5, 29.6 and 24.3%. After adjustment for other factors, heterosexual men appeared less likely to participate in trials compared with MSM [PR 0.79, 95% confidence interval (CI) 0.57, 1.11], while women were as likely to participate as MSM (PR 0.97, 95% CI 0.68, 1.39). The participation rate in Black patients (25.9%) was lower compared with non-Black patients (37.5%) (adjusted PR 0.80, 95% CI 0.60, 1.06).


CONCLUSIONS
In our clinical setting, gender did not appear to impact participation in HIV treatment trials, but Black patients were slightly less likely to participate in these trials. Considering the substantial proportion of HIV-infected patients who are Black, future trials need to consider strategies to incorporate such underrepresented populations.
Menezes
P
P
Division of Infectious Diseases, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA. menez001@med.unc.edu
Eron
J J
JJ
Leone
P A
PA
Adimora
A A
AA
Wohl
D A
DA
Miller
W C
WC
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D002986:Clinical Trials as Topic / Q000379:methods*; D003430:Cross-Sectional Studies; D005260:Female; D005783:Gender Identity; D015658:HIV Infections / Q000188:drug therapy* / Q000208:ethnology / Q000523:psychology; D006801:Humans; D008297:Male; D018579:Patient Selection; D044469:Racial Groups; D012725:Sexual Behavior
J Clin Oncol. 1999 Oct;17(10):3324-32
10506636
Am Stat. 2007 Feb;61(1):79-90
17401454
South Med J. 2001 Feb;94(2):212-22
11235037
N Engl J Med. 2002 May 2;346(18):1373-82
11986412
AIDS Patient Care STDS. 1996 Feb;10(1):21-4
11361654
BMJ. 1998 Mar 28;316(7136):989-91
9550961
N Engl J Med. 2006 Jan 19;354(3):251-60
16421366
J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):275-84
10969353
HIV Med. 2000 Jul;1(3):149-54
11737343
CMAJ. 1998 Dec 1;159(11):1359-65
9861204
AIDS Care. 2006;18 Suppl 1:S45-50
16938674
Fed Regist. 1993 Jul 22;58(139):39406-16
11645233
JAMA. 1992 Feb 19;267(7):954-7
1734108
J Clin Epidemiol. 2007 Oct;60(10):990-1001
17884592
HIV Med. 2000 Oct;1(4):212-8
11737351
J Gen Intern Med. 1999 Sep;14(9):537-46
10491242
MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
1361652
Am J Epidemiol. 2003 May 15;157(10):940-3
12746247
J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):34-40
16123679
AIDS Care. 2006;18 Suppl 1:S10-7
16938670
South Med J. 2007 Nov;100(11):1114-22
17984744
AIDS. 2004 Nov 19;18(17):2235-42
15577535
Am J Epidemiol. 2004 Apr 1;159(7):702-6
15033648
PLoS Med. 2006 Feb;3(2):e19
16318411
J Natl Med Assoc. 2007 Mar;99(3):242-50
17393948
Res Nurs Health. 2002 Feb;25(1):76-84
11807922
Cancer Detect Prev. 2006;30(1):24-33
16495020
J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 15;10(5):562-8
8548336
Clin Infect Dis. 2002 Aug 1;35(3):313-22
12115098
J Gen Intern Med. 2007 Jan;22(1):17-42
17351837
N Engl J Med. 2004 Apr 29;350(18):1850-61
15115831
BMC Med Res Methodol. 2003 Oct 20;3:21
14567763
J Gen Intern Med. 1997 Mar;12(3):150-7
9100139